Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study. The companies said the trial met its ...

Earlier this year Novo announced a collaboration with Gilead to investigate a combination of its GLP-1 class drug semaglutide with two potential NASH drugs from the US pharma’s pipeline.